Revvity reports strong second-quarter results and raises full-year guidance.
Revvity reported a 4% pro forma revenue growth and raised full-year guidance for 2026, while entering a definitive agreement to divest its China immunodiagnostics business.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day